CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last?

Stock Performance - CRISPR Therapeutics AG (CRSP) shares rallied 6.5% in the last trading session to close at $44.20, driven by higher trading volume compared to a typical session [1] - The stock has gained 1.4% over the past four weeks [1] - Tarsus Pharmaceuticals, Inc. (TARS) finished the last trading session 2.9% higher at $48.11, but has returned -13.5% over the past month [3] Financial Expectations - CRISPR Therapeutics is expected to post a quarterly loss of $1.20 per share, representing a year-over-year change of -209.1% [2] - Revenues are expected to be $10.83 million, down 94.6% from the year-ago quarter [2] - The consensus EPS estimate for CRISPR Therapeutics has remained unchanged over the last 30 days [3] - Tarsus Pharmaceuticals' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.70, representing a year-over-year change of +46.6% [4] Strategic Priorities - CRISPR Therapeutics outlined key strategic priorities related to the ongoing launch of Casgevy and certain pipeline goals for 2025, which may have driven the recent share price rally [1] Industry and Rankings - CRISPR Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry [3] - The stock currently carries a Zacks Rank 3 (Hold) [3] - Tarsus Pharmaceuticals currently boasts a Zacks Rank of 2 (Buy) [4]